57171-24-1

Basic information

• Product Name: 4-(4-methoxyphenyl)dihydro-2H-pyran-2,6(3H)-dione
• CAS NO: 57171-24-1
• Molecular Formula: C₁₂H₁₂O₄
• Molecular Weight: 220.2213
• Mol File: 57171-24-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 402.8°C at 760 mmHg
• Flash Point: 182.3°C
• Density: 1.232g/cm³
• Vapor Pressure: 1.07E-06mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: 4-(4-methoxyphenyl)dihydro-2H-pyran-2,6(3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methoxyphenyl)dihydro-2H-pyran-2,6(3H)-dione(57171-24-1)
• EPA Substance Registry System: 4-(4-methoxyphenyl)dihydro-2H-pyran-2,6(3H)-dione(57171-24-1)

Safety Data

• Hazardous Substances Data: 57171-24-1(Hazardous Substances Data)

Upstream product

• 14143-50-1 2-(4-methoxy-phenyl)-propane-1,1,3-tricarboxylic acid triethyl ester 
• 24393-56-4 ethyl p-methoxycinnamate 
• 6630-90-6 ethyl 2,2'-(4-methoxybenzal)bis-acetoacetate 
• 123-11-5 4-methoxy-benzaldehyde 
• 33868-73-4 diethyl 3-(4-methoxyphenyl)pentanedioate 
• 33868-91-6 3-(4-methoxyphenyl)glutaric acid 
• 66066-43-1 3-(4-methoxyphenyl)-2-pentenedioic acid 
• 463-51-4 Ketene 

Downstream Products

• 109936-02-9 1-(3-hydroxy-4-methoxy-benzyl)-4-(4-methoxy-phenyl)-piperidine-2,6-dione 
• 65321-71-3 3,5-bis-(4-methoxy-phenyl)-5-oxo-valeric acid 
• 92410-48-5 5-N-Phenyl-3-p-methoxyphenylglutaramic acid 
• 75436-96-3 5-(2,4-dimethoxy-phenyl)-3-(4-methoxy-phenyl)-5-oxo-valeric acid 
• 4962-67-8 N-(3,4-Dimethoxy-phenaethyl)-3-(4-methoxyphenyl)-glutarsaeure-monoamid 
• 76734-01-5 N-(6-methyl-2-pyridyl)-4-(p-methoxyphenyl)piperidine-2,6-dione 
• 92410-42-9 5-N-(n-Propyl)-3-p-methoxyphenylglutaramic acid 
• 92410-45-2 5-N-(n-Hexyl)-3-p-methoxyphenylglutaramic acid 
• 92410-46-3 5-N-Cyclohexyl-3-p-methoxyphenylglutaramic acid 
• 92410-41-8 5-N-Ethyl-3-p-methoxyphenylglutaramic acid 
• 92410-44-1 5-N-(n-Pentyl)-3-p-methoxyphenylglutaramic acid 
• 117192-43-5 3-(4-Methoxyphenyl)pentanedioic acid 5-thiosemicarbazide 
• 79323-07-2 1-{3-[4-(4-Chloro-phenyl)-piperazin-1-yl]-propyl}-4-(4-methoxy-phenyl)-piperidine-2,6-dione 
• 79323-05-0 1-{3-[4-(2-Chloro-phenyl)-piperazin-1-yl]-propyl}-4-(4-methoxy-phenyl)-piperidine-2,6-dione 

Relevant articles and documents

Synthesis and biological evaluation of pentanedioic acid derivatives as farnesyltransferase inhibitors

Structure-based virtual screening of a commercial library identified pentanedioic acid derivatives (6 and 13b) as a kind of novel scaffold farnesyltransferase inhibitors (FTIs). Chemical modifications of the lead compounds, biological assays and analysis of the structure-activity relationships (SAR) were conducted to discover more potent FTIs. Some of them displayed excellent inhibition against FTase, and among them, the most active compound 13n with an IC50 value of 0.0029 μM and SAR analysis might be helpful to the discovery of more potent FTIs. This journal is

Enzymatic desymmetrization of 3-arylglutaric acid anhydrides

Optically active (R)- and (S)-3-arylglutaric acid monoesters 3 were synthesized in quantitative yields and good stereoselectivities by lipase-catalyzed desymmetrization of the corresponding 3-arylglutaric anhydrides 2 with alcohols. It was observed that the stereochemical outcome of the reaction was influenced by the substituents present on the aromatic ring. The influence of the enzyme, alcohol, and solvent was systematically examined. Absolute configurations of the monoesters 3 were assigned by chemical correlation to corresponding lactones 4.

Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists

The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.